NewAmsterdam Pharma (NAMS) Change in Accured Expenses (2023 - 2026)

NewAmsterdam Pharma has reported Change in Accured Expenses for 4 years, with the latest figure at -$10.3 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 108.56% year-over-year to -$10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 55.3% YoY) and the FY2025 annual result came in at $2.4 million, up 45.2% from the prior year.
• Change in Accured Expenses slipped to -$10.3 million in Q1 2026 per NAMS's latest filing, from $5.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $9.3 million in Q3 2023 and troughed at -$10.3 million in Q1 2026.
• A 4-year average of -$55846.2 and a median of $402000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 431.0% in 2025, down 258.65% in 2025.
• Over 4 years, Change in Accured Expenses stood at -$5.8 million in 2023, then jumped by 141.3% to $2.4 million in 2024, then jumped by 122.39% to $5.3 million in 2025, then tumbled by 294.03% to -$10.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$10.3 million, $5.3 million, and $638000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.